Zepbound (Tirzepatide) Hair Loss: Alternatives Without This Side Effect

Does Zepbound cause hair loss?

Yes. Hair loss (alopecia) appears in the Zepbound label's table of adverse reactions reported in at least 2% of patients and more often than placebo: 5% at 5 mg, 4% at 10 mg and 5% at 15 mg, against 1% on placebo [1]. The label also lists hair loss among the most common adverse reactions, reported in at least 5% of treated patients [1].

Those rates come from the pooled weight-management trials (SURMOUNT-1 and SURMOUNT-2), which followed adults with obesity or overweight for up to 72 weeks: 958 on placebo, 630 on 5 mg, 948 on 10 mg and 941 on 15 mg [1]. They are not SURMOUNT-1 numbers alone.

What the label links hair loss to

The label says hair loss was associated with weight reduction [1]. It also records a sharp sex difference: 7.1% of women versus 0.5% of men on Zepbound, compared with 1.3% of women and 0% of men on placebo [1].

A 2026 systematic review of 24 studies on GLP-1 drugs and hair loss found that telogen effluvium and androgenetic alopecia were the subtypes most often reported, that tirzepatide, which produced the largest weight loss, was most often linked to telogen effluvium, and that rapid weight loss was a potential contributor [2]. A potential contributor is not a proven cause, and the review's authors say large prospective randomized trials are still needed to establish causality [2].

Is there a weight-loss drug that does not cause hair loss?

The broadest comparison comes from that systematic review: among GLP-1 receptor agonists, semaglutide and tirzepatide had the highest reported hair-loss rates and the most frequent signals in pharmacovigilance databases, while liraglutide, dulaglutide, lixisenatide and exenatide had lower reported risk, though far fewer studies looked at those drugs [2].

Reports from the FDA Adverse Event Reporting System do not agree with each other. One disproportionality analysis found a positive alopecia signal for semaglutide and a lower, non-significant signal for tirzepatide [3]. Another analysis of the same database reported alopecia relatively more often with tirzepatide than with semaglutide [4]. Spontaneous reports reflect reporting patterns rather than comparative clinical risk or causality [4], so they cannot say which drug causes more hair loss.

Does a lower dose mean less hair loss?

The label data show no dose pattern: 5% at 5 mg, 4% at 10 mg and 5% at 15 mg, against 1% on placebo [1]. The lowest maintenance dose produced the same reported rate as the highest one in those trials.

What about stopping Zepbound?

In the pooled trials, no Zepbound-treated patient discontinued treatment because of hair loss, while one placebo-treated patient did [1]. Stopping tirzepatide was followed by weight regain in SURMOUNT-4: 670 adults who had lost a mean 20.9% of body weight during a 36-week lead-in were randomized to continue tirzepatide or switch to placebo, and from week 36 to week 88 weight changed by -5.5% with continued treatment versus +14.0% after the switch [5].

Who reports hair loss more often?

Women, consistently. The label's 7.1% versus 0.5% split is the clearest number [1], and the systematic review found women disproportionately affected across the literature it covered [2]. A cross-sectional survey of 254 people using GLP-1 receptor agonists for weight loss (Mounjaro, Ozempic, Saxenda or Victoza; 71.3% female) found men less likely than women to report hair loss (adjusted odds ratio 0.36) and Mounjaro users more likely than users of the other injections (adjusted odds ratio 3.02) [6]. That was a self-reported questionnaire from one country, so it describes who reports hair loss rather than a measured incidence.

Timing and regrowth

The label's hair-loss statement covers the link to weight reduction and the sex difference; it gives no timing for shedding or regrowth [1]. The authors of the cross-sectional survey describe this type of hair loss as typically non-scarring and reversible [6], but that is their characterization of what they recorded, not a follow-up measurement.